Statistics from Altmetric.com
We read with great interest the article by Genovese et al1 on the effect of the B-cell activating factor (BAFF) antagonist tabalumab in rheumatoid arthritis patients with inadequate response to tumour necrosis factor (TNF)a blockade. The results of this study indicated a moderate effect of tabalumab early (week 6/week 9) after initiation of therapy, both in terms of clinical as well as laboratory markers of disease activity, which however was not significantly sustained later on in the course of treatment (week 16).
In the previous decade, biological therapies that target the B cell have become established in the treatment of rheumatoid …
Competing interests None.
Provenance and peer review Not commissioned; internally peer reviewed.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.